NASDAQ:AMYT Amryt Pharma - AMYT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. $14.55 -0.04 (-0.27%) (As of 03/28/2023 05:12 PM ET) Add Compare Share Share Today's Range$14.55▼$14.6050-Day Range$14.55▼$14.7052-Week Range$6.41▼$14.77Volume1.68 million shsAverage Volume741,066 shsMarket Capitalization$930.62 millionP/E RatioN/ADividend YieldN/APrice Target$15.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Amryt Pharma MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside6.0% Upside$15.42 Price TargetShort InterestHealthy0.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.13) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 starsMedical Sector923rd out of 1,002 stocksPharmaceutical Preparations Industry446th out of 488 stocks 2.0 Analyst's Opinion Consensus RatingAmryt Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.42, Amryt Pharma has a forecasted upside of 6.0% from its current price of $14.55.Amount of Analyst CoverageAmryt Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.19% of the outstanding shares of Amryt Pharma have been sold short.Short Interest Ratio / Days to CoverAmryt Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amryt Pharma has recently increased by 56.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmryt Pharma does not currently pay a dividend.Dividend GrowthAmryt Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMYT. Previous Next 1.9 News and Social Media Coverage News SentimentAmryt Pharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Amryt Pharma this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amryt Pharma insiders have not sold or bought any company stock.Percentage Held by Institutions71.31% of the stock of Amryt Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amryt Pharma are expected to grow in the coming year, from ($0.13) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amryt Pharma is -242.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amryt Pharma is -242.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmryt Pharma has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amryt Pharma (NASDAQ:AMYT) StockAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Stock News HeadlinesMarch 17, 2023 | benzinga.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsFebruary 16, 2023 | finance.yahoo.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023March 28, 2023 | The Oxford Club (Ad)JP Morgan analyst: Oil to hit $380 per barrelJP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.January 9, 2023 | msn.comWhy CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving PremarketJanuary 9, 2023 | msn.comEuropean drugmakers including AstraZeneca pony up for U.S.-listed biopharmasJanuary 6, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Amryt Pharma (AMYT)January 5, 2023 | finance.yahoo.comAmryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFHNovember 7, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)March 28, 2023 | Porter & Company (Ad)Biden’s Big Lie…Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. November 6, 2022 | seekingalpha.comAmryt Pharma PLC (AMYT) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comAmryt Reports Q3 2022 Financial and Operational ResultsOctober 31, 2022 | msn.comLigand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 27, 2022 | finance.yahoo.comAmryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 25, 2022 | finance.yahoo.comThe British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis BullosaOctober 24, 2022 | finance.yahoo.comAmryt Supports Global EB Awareness Week 2022October 19, 2022 | finance.yahoo.comAmryt to Report Q3 2022 Results on November 3, 2022September 23, 2022 | finance.yahoo.comAmryt Supports FH Awareness Day – September 24, 2022September 16, 2022 | marketwatch.comAmryt Pharma Gets CHMP Backing for Mycapssa in Acromegaly >AMYTSeptember 16, 2022 | finance.yahoo.comCHMP adopts positive opinion for Mycapssa® for the treatment of AcromegalySeptember 8, 2022 | msn.comAmryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder CandidateSeptember 8, 2022 | finance.yahoo.comAmryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great BritainSeptember 7, 2022 | finance.yahoo.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022August 9, 2022 | finance.yahoo.comCan Amryt Pharma PLC Sponsored ADR (AMYT) Climb 187% to Reach the Level Wall Street Analysts Expect?August 4, 2022 | finance.yahoo.comAmryt Reports Record Q2 2022 ResultsJuly 21, 2022 | finance.yahoo.comAmryt to Report Q2 2022 Results on August 4, 2022July 14, 2022 | markets.businessinsider.comAmryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor CandidateJuly 14, 2022 | marketwatch.comAmryt Gets FDA Orphan Designation for Mycapssa in Carcinoid Syndrome >AMYTSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Company Calendar Last Earnings11/05/2020Today3/28/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMYT CUSIPN/A CIK1783010 Webwww.amrytpharma.com Phone353-1518-0200FaxN/AEmployees2,020Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.42 High Stock Price Forecast$17.00 Low Stock Price Forecast$14.50 Forecasted Upside/Downside+6.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1 million Net Margins-8.19% Pretax Margin-0.56% Return on Equity1.70% Return on Assets0.75% Debt Debt-to-Equity Ratio0.64 Current Ratio1.57 Quick Ratio0.94 Sales & Book Value Annual Sales$222.54 million Price / Sales4.18 Cash Flow$0.98 per share Price / Cash Flow14.87 Book Value$5.58 per share Price / Book2.61Miscellaneous Outstanding Shares63,960,000Free FloatN/AMarket Cap$930.62 million OptionableNot Optionable Beta0.86 Key ExecutivesDr. Joseph A. Wiley (Age 51)CEO & Director Comp: $1.65MMr. Rory P. Nealon (Age 54)CFO, COO & Company Sec. Comp: $890kMs. Elizabeth Varki Jobes J.D. (Age 55)Chief Compliance Officer Mr. John McEvoyGen. CounselMr. Stephen JoyceHead of Marketing & Head of APACMs. Julie EastwoodHead of HRDr. Helen PhillipsHead of Medical AffairsMs. Sheila M. Frame (Age 60)Pres of Americas Dr. Tracy CunninghamChief Medical OfficerMr. Jordi CasalsPres of EMEA RegionMore ExecutivesKey CompetitorsGemini TherapeuticsNASDAQ:GMTXVerve TherapeuticsNASDAQ:VERVAlbireo PharmaNASDAQ:ALBORhythm PharmaceuticalsNASDAQ:RYTMEQRxNASDAQ:EQRXView All CompetitorsInstitutional OwnershipStonepine Capital Management LLCBought 105,506 shares on 2/15/2023Ownership: 9.902%Silverarc Capital Management LLCBought 4,695 shares on 2/15/2023Ownership: 0.302%Millennium Management LLCSold 120,735 shares on 2/15/2023Ownership: 0.216%Morgan StanleySold 4,240 shares on 2/15/2023Ownership: 0.130%Virtu Financial LLCBought 12,442 shares on 2/15/2023Ownership: 0.019%View All Institutional Transactions AMYT Stock - Frequently Asked Questions Should I buy or sell Amryt Pharma stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMYT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMYT, but not buy additional shares or sell existing shares. View AMYT analyst ratings or view top-rated stocks. What is Amryt Pharma's stock price forecast for 2023? 5 analysts have issued 1-year target prices for Amryt Pharma's shares. Their AMYT share price forecasts range from $14.50 to $17.00. On average, they expect the company's share price to reach $15.42 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View analysts price targets for AMYT or view top-rated stocks among Wall Street analysts. How have AMYT shares performed in 2023? Amryt Pharma's stock was trading at $7.30 on January 1st, 2023. Since then, AMYT shares have increased by 99.3% and is now trading at $14.55. View the best growth stocks for 2023 here. Are investors shorting Amryt Pharma? Amryt Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 121,200 shares, an increase of 56.2% from the February 28th total of 77,600 shares. Based on an average trading volume of 646,300 shares, the short-interest ratio is presently 0.2 days. View Amryt Pharma's Short Interest. When is Amryt Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our AMYT earnings forecast. How were Amryt Pharma's earnings last quarter? Amryt Pharma plc (NASDAQ:AMYT) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.66. The firm earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). What is Amryt Pharma's stock symbol? Amryt Pharma trades on the NASDAQ under the ticker symbol "AMYT." Who are Amryt Pharma's major shareholders? Amryt Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.90%), Handelsbanken Fonder AB (2.21%), Armistice Capital LLC (1.53%), Wells Fargo & Company MN (0.46%), Silverarc Capital Management LLC (0.30%) and Millennium Management LLC (0.22%). How do I buy shares of Amryt Pharma? Shares of AMYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amryt Pharma's stock price today? One share of AMYT stock can currently be purchased for approximately $14.55. How much money does Amryt Pharma make? Amryt Pharma (NASDAQ:AMYT) has a market capitalization of $930.62 million and generates $222.54 million in revenue each year. The company earns $1 million in net income (profit) each year or ($0.06) on an earnings per share basis. How many employees does Amryt Pharma have? The company employs 2,020 workers across the globe. How can I contact Amryt Pharma? Amryt Pharma's mailing address is DEPT 920A 196 HIGH ROAD WOOD GREEN, LONDON X0, D02 CR98. The official website for the company is www.amrytpharma.com. The company can be reached via phone at 353-1518-0200 or via email at ir@amrytpharma.com. This page (NASDAQ:AMYT) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.